Insider Moves: Major Stock Sale at Hims & Hers Health!

New insider activity at Hims & Hers Health ( (HIMS) ) has taken place on August 12, 2025.

CLO Soleil Boughton recently sold 2,572 shares of Hims & Hers Health stock, amounting to a total transaction value of $132,818.

Recent Updates on HIMS stock

In the last 24 hours, Hims & Hers Health has experienced notable developments, with its stock showing mixed sentiment and price movements. Deutsche Bank raised its price target for the company, citing strong growth metrics and strategic expansions, despite some financial challenges. The company’s recent Q2 earnings call highlighted a 73% year-over-year revenue growth and a 31% increase in its subscriber base, driven by strategic market expansions and innovative healthcare offerings. However, challenges such as a decline in GLP-1 revenue, negative free cash flow, and rising general and administrative costs were noted. Bank of America expressed a more cautious outlook, pointing to these financial hurdles as reasons for its skepticism. Overall, the company’s forward-looking guidance remains optimistic, with plans for continued growth and international expansion.

Spark’s Take on HIMS Stock

According to Spark, TipRanks’ AI Analyst, HIMS is a Outperform.

Hims & Hers Health’s strong financial performance and positive earnings call sentiment are the primary drivers of its stock score. The company’s robust revenue growth, strategic partnerships, and expansion efforts support its growth trajectory. However, the high P/E ratio suggests that the stock may be overvalued, posing a risk if growth expectations are not met. Technical indicators support a bullish trend, adding to the positive outlook.

To see Spark’s full report on HIMS stock, click here.

More about Hims & Hers Health

YTD Price Performance: 98.33%

Average Trading Volume: 41,986,807

Technical Sentiment Signal: Buy

Current Market Cap: $11.3B